The Lynx Group
Cholangiocarcinoma News

Press Releases

Web Exclusives — October 11, 2022
Helsinn Therapeutics, Inc. has released an important announcement about the discontinuation of distribution of TRUSELTIQ® (infigratinib) capsules as of the first quarter of 2023. It is important to note that this discontinuation is not for safety or efficacy reasons but is based on difficulties in recruiting and enrolling study subjects for the required confirmatory clinical trial.
Read More

Web Exclusives — February 3, 2021
February 1, 2021 (Cranbury, NJ): The Cholangiocarcinoma Foundation (CCF) designated The Lynx Group (TLG) as a “Trusted Partner,” 1 of only 4 organizations globally. A CCF “Trusted Partner” shares the CCF mission: to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). These 4 esteemed partners are fundamental to the Foundation’s growth and ability to provide high-quality programs and services to the CCA community.
Read More

Web Exclusives — December 23, 2020
As the end of this year draws near, we at The Lynx Group would like to take this opportunity to thank all of you for an amazing 2020. We also share a celebration of our victories and accomplishments with everyone, while reflecting on ways to improve as we progress into the new year! The success of The Lynx Group is based on the effective and vibrant relationships we have forged over the years; we simply wouldn’t be where we are without you. We are extremely grateful for the opportunity to work with, and for you!
Read More


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: